A Look At Celldex Therapeutics (CLDX) Valuation After Recent Weak Trading Performance [Yahoo! Finance]
Celldex Therapeutics, Inc. (CLDX)
Last celldex therapeutics, inc. earnings: 11/12 08:01 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.celldex.com
Company Research
Source: Yahoo! Finance
Celldex Therapeutics (CLDX) has drawn attention after recent trading, with the stock showing negative returns over the past day, week, month, and past 3 months, as well as year to date and over the past year. See our latest analysis for Celldex Therapeutics. Recent trading has been weak, with a 1 day share price return of a 5.57% decline and a 7 day share price return of a 5.35% decline. That softer momentum aligns with a 3 year total shareholder return of a 43.33% decline compared with a 5 year total shareholder return of 12.34%. If Celldex's recent pullback has you reassessing biotech exposure, it could be a useful moment to scan other healthcare stocks that might fit your risk and return preferences. With Celldex showing weak recent returns but trading at a large discount to some valuation estimates, the key question is whether you are seeing a mispriced biotech story or a stock that already reflects its future prospects. Our DCF model estimates Celldex Therapeutics' fut
Show less
Read more
Impact Snapshot
Event Time:
CLDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLDX alerts
High impacting Celldex Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CLDX
News
- Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026GlobeNewswire
- Celldex Therapeutics (CLDX) was upgraded by Wolfe Research from "peer perform" to "outperform". They now have a $44.00 price target on the stock.MarketBeat
- A Look At Celldex Therapeutics (CLDX) Valuation After Recent Share Price Weakness And Strong 1 Year Return [Yahoo! Finance]Yahoo! Finance
- Celldex Therapeutics Touts Barzolvolimab Phase III CSU Momentum, Lays Out 2026 Data Catalysts [Yahoo! Finance]Yahoo! Finance
- Celldex Therapeutics Highlights Barzolvolimab Phase 3 Wins, New Trials at TD Cowen Conference [Yahoo! Finance]Yahoo! Finance
CLDX
Earnings
- 2/25/26 - Miss
CLDX
Sec Filings
- 3/26/26 - Form SCHEDULE
- 3/10/26 - Form SCHEDULE
- 2/25/26 - Form 10-K
- CLDX's page on the SEC website